Business
Graft Bio signs manufacturing services agreement
Graft Bio signs manufacturing services agreement.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\n\n 23 August 2023\nGraft Polymer (UK) PLC\nGraft Bio signs manufacturing services agreement for production of haemostatic wound care products \n \nGraft Polymer (UK) plc (\"Graft Polymer\", LSE: GPL), the specialist chemicals company offering modified and alloyed polymer and bio-polymer solutions for refiners, compounders and processors, announces the signing of a manufacturing service agreement with a prominent partner (the \"Partner\") in the Israeli pharma market, including GPL acting as a lead contract manufacturing organization ('CMO').\nUnder the agreement, Graft Polymer is to provide manufacturing services from its GraftBio production facility in Slovenia, which is now fully operational. Graft Polymer has been contracted by the partner to produce its patented haemostatic powder following a recent, successful pilot scheme.\nThe customer has an innovative product whose manufacturing requires deep-seated understanding of and experience with polymers. The benefits of the product are its ability to change from a self-emulsifying powder to a gel on contact with blood, meaning that it can penetrate a wound and clot the blood effectively from within. As such, it has a wide range of applications and Graft Polymer will work with our partner to enhance the product in due course, leveraging its SNEDDS (self-nanoemulsifying drug delivery system) technology.\nThe benefits of this service ag...